Inhalation Sciences secures product service contract worth 47,000 Euro

(Stockholm, Sweden, 29 December,2023) Inhalation Sciences AB (ISAB) has secured a product service contract with a worth of 47,000 Euro on its instruments at the facilities of a large European pharma company. The order reaffirms the client’s strong commitment to its continuing use of ISAB instruments on their robust portfolio of inhaled therapies.

The client is a long-standing ISAB customer. Its suite of in-house ISAB instruments has played an important role in developing its competitive and substantial pipeline of inhaled therapeutics. The new contract will cover the service and maintenance of their inhouse instruments, ensuring optimal performance.

ISAB CEO Manoush Masarrat: “we’re pleased to receive this new order and appreciate the continued trust of our customer. Their long-sighted approach demonstrates their commitment to developing new therapies in an efficient and risk-free way as possible. We look forward to supporting them over the coming years”.